# ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

> **NCT01903330** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Epitopoietic Research Corporation** · enrollment: 84 (estimated)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **DRUG:** ERC1671
- **DRUG:** GM-CSF
- **DRUG:** Cyclophosphamide
- **DRUG:** Oral Control (Sucrose pill)
- **DRUG:** Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))
- **DRUG:** Bevacizumab/Bevacizumab Biosimilar

## Key facts

- **NCT ID:** NCT01903330
- **Lead sponsor:** Epitopoietic Research Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-03
- **Primary completion:** 2026-03
- **Final completion:** 2026-06
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903330, "ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01903330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*